BioNotebook: Bubble speculation, stock offerings, IPOs and venture capital funding
This article was originally published in Scrip
Are we in a bubble and is it about to burst? You could say that's the question of the moment, but really it's the question that everyone in and around the biotechnology industry has been asking for the past year due to skyrocketing public biotech company values and the soaring initial public offering market.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.